This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Okay. I think we will go ahead and get started here. For those of you who don't know me, I'm (inaudible) MOS Biotech team and I'm joined right now by the team from Array BioPharma. So, we have Ron Squarer, CEO; Michael Carruthers, CFO; and Kevin Kock, CSO of Array. Thank you guys for joining us. Few housekeeping things before we get started. All disclosures, personal holding disclosures and Morgan Stanley disclosures are in the Morgan Stanley website. MorganStanley.com/researchdisclosures. For those of you who haven't been here before this is open Q&A, if you are free to join us at any point if you have a question.
With that I'll turn it over to Ron and team and guys you have a lot of drugs in development a lot of stuff going on, so maybe to start if you could just give us some brief overview of the company and their drugs in recent events.
Thank you for that introduction, I'm going to be making some forward-looking statements, so please consult our 10-K for a full discussion of risk and get specifically Kevin Kock, our Chief Scientific Officer here also one of the founders of the company, Mike Carruthers, our CFO, we also in the audience have another one of our Founders and our Chairman, Kyle Lefkoff.
So, it has been a very exciting time indeed. We are about over 160% year-to-date, over 60% in the last three months, in terms of our share price and this is really been catalyzed by their progress we have made with our portfolio looking at as many as five potential Phase 3 starts between now and the end of next year.